A seed fund founded by a China-based investment firm supports early stage companies and helps startups from the US and Europe expand successfully into the China market. The fund is an active early stage medtech and biotech investor. The firm supports companies throughout the development process and typically invests up to $500,000 per company. The seed fund has particular success in fostering joint development initiatives between U.S. and China-based companies, and invests in companies based in the U.S., China and Europe.
The fund invests in early stage therapeutics, medical devices, diagnostics, and healthcare services and IT that may still need FDA approval and have a fast-track clinical development platform approved by the China SFDA. The firm is particularly interested in companies that have clinical development plans and interest in China. The fund is also open to lab equipment and drug development enabling technology.
The fund supports companies who have an international business model with desire to expand into the US, China, and/or Europe.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment